

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Vital Healthcare Property Trust
Date this disclosure made:	24 June 2016
Date of last disclosure:	6 April 2016
Director or senior manager giving disclosure	
Full name(s):	Claire Higgins
Name of listed issuer:	Vital Healthcare Property Trust
Name of related body corporate (if applicable):	
Position held in listed issuer:	Director of Vital Healthcare Management Limited
Summary of acquisition or disposal of relevant interest (excluding specified derivative	ves)
	,
Class of affected quoted financial products:	Ordinary units
Nature of the affected relevant interest(s):	Legal and beneficial owner of units
For that relevant interest-	
Number held in class before acquisition or disposal:	59,713
Number held in class after acquisition or disposal:	60,280
Current registered holder(s):	Adam L Higgins Superannuation Fund
Registered holder(s) once transfers are registered:	
Summary of acquisition or disposal of specified derivatives relevant interest (if appli	,
Class of underlying financial products:	N/A
Details of affected derivative-	N/A
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	24 June 2016
Nature of transaction:	Distribution Reinvestment Plan
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily by converted into	1 269 00
a cash value, describe the consideration:	\$ 1,268.90
Number of financial products to which the transaction related: If the issuer has a financial products trading policy that prohibits directors or senior	567
managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	k1.
Whether prior written clearance was provided to allow the acquisition or disposal to	No
proceed during the closed period:	
Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	N/A
Nature of relevant interest:	N/A
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	
Details of derivative,-	ş-
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	Millarion
Date of signature:	24 June 2016
Name and title of authorised person:	Stuart Harrison - Company Secretary

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	[million 1 million 1 milli
Name of listed issuer:	Vital Healthcare Property Trust
Date this disclosure made:	24 June 2016
Date of last disclosure:	6 April 2016
Director or senior manager giving disclosure	
Full name(s):	Andrew Evans
Name of listed issuer:	Vital Healthcare Property Trust
Name of related body corporate (if applicable):	The Treatment of Test
	Director of Vital Healthcare
Position held in listed issuer:	Management Limited
Summary of acquisition or disposal of relevant interest (excluding specified derivative)	es)
Class of affected quoted financial products:	Ordinary units
Nature of the affected relevant interest(s):	Legal and beneficial owner of certain units, and Non-Beneficial owner (units held by the registered holder for the Graeme Horsley No 3 Trust of which Andrew Evans is a trustee) of certain units
For that relevant interest-	
Number held in class before acquisition or disposal:	570,373
Number held in class after acquisition or disposal:	575,784
Current registered holder(s):	The Bassett Trust and Graeme Horsley No 3 Trust
Registered holder(s) once transfers are registered:	
Summary of acquisition or disposal of specified derivatives relevant interest (if applied Type of affected derivative:	cable) N/A
Class of underlying financial products:	N/A
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	24 June 2016
Nature of transaction:	Distribution Reinvestment Plan
Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$ 12,120.42
Number of financial products to which the transaction related:	5,411
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	5,711
Whether relevant interests were acquired or disposed of during a closed period:	No

Whether prior written clearance was provided to allow the acquisition or disposal to	
proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	N/A
Nature of relevant interest:	N/A
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	My Gariery
Date of signature:	24 June 2016
Name and title of authorised person:	Stuart Harrison - Company Secretary

Notes

Use this form to disclose all the acquisitions—and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

T- N7V / !!	
To NZX Limited; and	[····
Name of listed issuer:	Vital Healthcare Property Trust
Date this disclosure made:	24 June 2016
Date of last disclosure:	6 April 2016
Director or conjor manager giving displayure	
Director or senior manager giving disclosure Full name(s):	Crooms Harston
Name of listed issuer:	Graeme Horsley Vital Healthcare Property Trust
	Vital Healincare Property Trust
Name of related body corporate (if applicable):	Diverse of Maria I to a laborary
Position held in listed issuer:	Director of Vital Healthcare Management Limited
	Management Emilia
Summary of acquisition or disposal of relevant interest (excluding specified derivation)	ves)
Class of affected quoted financial products:	Ordinary units
otobo of director spotson menoral products.	Beneficial owner (the units are held by
Nature of the affected relevant interest(s):	the registered holder for the Graeme Horsley No 3 Trust of which Graeme Horsley is a trustee and beneficiary)
For that relevant interest-	
Number held in class before acquisition or disposal:	230,426
Number held in class after acquisition or disposal:	232.612
Current registered holder(s):	Graeme Horsley No 3 Trust
Registered holder(s) once transfers are registered:	Glaefile Florsley No 3 Trusti
registered riolder(3) drice transiers are registered.	
Summary of acquisition or disposal of specified derivatives relevant interest (if appl	icable)
Type of affected derivative:	N/A
Class of underlying financial products:	N/A
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant	
interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
Date of transaction:	24 June 2016
Nature of transaction:	Distribution Reinvestment Plan
Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily by converted into	
a cash value, describe the consideration:	\$ 4,896.55
Number of financial products to which the transaction related:	2186
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	110
Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal: Class of quoted financial products: N/A Nature of relevant interest: N/A For that relevant interest,-Number held in class: Current registered holder(s): For a derivative relevant interest,-Type of derivative: Details of derivative,-The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: For that derivative relevant interest,-Parties to the derivative: If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: Certification I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. Signature of director or officer:

Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

Mossing

24 June 2016

Stuart Harrison - Company Secretary

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.